AAMU
ARRY

Amundi Asset Management US’s Array Biopharma Inc ARRY Stock Holding History

Amundi Asset Management US’s Portfolio ARRY Stock Details ARRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-54,900
Closed -$702K – 1623
2017
Q4 		$702K Buy
+54,900
New +$624K ﹤0.01% 1247

Other funds holding ARRY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Amundi Asset Management US's ARRY Position: Q1 2018 in Review

Amundi Asset Management US sold out of Array Biopharma Inc (ARRY) in Q1 2018, closing a stake of 54,900 shares — an estimated $702K sold.

Amundi Asset Management US first reported a position in ARRY in Q4 2017 and held it in 1 quarter. The position peaked at $702K in Q4 2017. 235 funds tracked by Wall St. Rank hold ARRY as of Q1 2018.

  • Amundi Asset Management US reported no remaining Array Biopharma Inc position as of Q1 2018 after selling out during the quarter.
  • Amundi Asset Management US sold 54,900 Array Biopharma Inc shares in Q1 2018, an estimated $702K.
  • Amundi Asset Management US first reported a position in Array Biopharma Inc in Q4 2017 and held it in 1 quarter.
  • Amundi Asset Management US's Array Biopharma Inc position peaked at $702K in Q4 2017.
  • 235 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q1 2018.

Based on Amundi Asset Management US's 13F filing for Q1 2018, filed 15 May 2018.